Company news
Inflarx N.v. (NASDAQ:IFRX) news
Inflarx N.v. news releases on 6ix. Latest, Sep 3, 2024: InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement…
Press releases — page 2
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
September 2, 2024
InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
August 7, 2024
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
June 23, 2024
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
May 20, 2024
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
May 7, 2024
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
April 29, 2024
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
March 20, 2024
InflaRx Appoints Jan Medina as Head of Investor Relations
February 21, 2024
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
January 24, 2024
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
January 3, 2024
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
November 5, 2023
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
October 31, 2023
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
September 10, 2023
InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
August 29, 2023
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
August 9, 2023
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
June 27, 2023
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
June 20, 2023
InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
May 10, 2023
InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million
April 17, 2023
InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares
April 13, 2023
InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares
April 11, 2023
InflaRx Announces Public Offering of Ordinary Shares
April 10, 2023
InflaRx Reports Full Year 2022 Financial and Operating Results
March 21, 2023
InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients
January 4, 2023
InflaRx Announces Amendment of Co-Development Agreement and Additional Equity Investment by Staidson in Connection with Regulatory Filing in China for Anti-C5a-Antibody for Treatment of COVID-19
December 20, 2022
InflaRx Reports Third Quarter 2022 Financial & Operating Results
November 8, 2022
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904
November 8, 2022
InflaRx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
September 28, 2022
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
September 7, 2022
InflaRx Reports Second Quarter 2022 Financial & Operating Results
August 4, 2022
InflaRx Announces Plans to Apply for Emergency Use Authorization from the US FDA for Vilobelimab for Treatment of Critically Ill COVID-19 Patients
July 25, 2022
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum
July 5, 2022
InflaRx Provides Development Update for Vilobelimab in Pyoderma Gangrenosum and Severe COVID-19
June 28, 2022
InflaRx Reports First Quarter 2022 Financial and Operating Results and Provides Strategic Update
May 11, 2022
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
March 30, 2022
InflaRx Reports Full Year 2021 Financial and Operating Results
March 23, 2022
InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
March 16, 2022
InflaRx Announces Vilobelimab Trial in Pyoderma Gangrenosum Selected for Late-Breaker Oral Presentation at 2022 AAD Annual Meeting
March 7, 2022
InflaRx Provides Update on Development Plans for Vilobelimab in Hidradenitis Suppurativa
February 27, 2022
InflaRx Reports Progress in Ongoing Phase II Clinical Trial with Vilobelimab in Cutaneous Squamous Cell Carcinoma
February 15, 2022
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
January 9, 2022
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa
January 4, 2022
InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab in ANCA-associated Vasculitis (AAV)
November 14, 2021
InflaRx Reports Third Quarter 2021 Financial & Operating Results
November 4, 2021
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
October 26, 2021
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
October 11, 2021
InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint
September 7, 2021
InflaRx Announces Positive Data from Second Interim Analysis of Ongoing Phase IIa Open Label Study with Vilobelimab in Pyoderma Gangraenosum
August 9, 2021
InflaRx Reports Second Quarter 2021 Financial & Operating Results
August 4, 2021
InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab
June 7, 2021